Previous studies by our group have shown that treatment of rabbit aortic endothelial cells (RAECs) for 4 to 24 hours with minimally oxidized low-density lipoprotein (MM-LDL) but not highly oxidized LDL or native LDL increased monocyte but not neutrophil binding to the endothelial monolayer. 34 Binding was maximal after 4 hours of treatment. Other groups have shown that injection of highly oxidized LDL into animals increases both monocyte and neutrophil binding to capillary endothelial cells, probably mediated in part by increases in leukotriene levels in the plasma activating the leukocytes. 56 In vitro studies have shown that treatment of human umbilical vein endothelial cells (HUVECs) with highly oxidized LDL for short periods induced U937 binding to the endothelium, 7 but other groups have not found an increase in the binding of monocytic cells to human umbilical vein endothelium after treatment of the endothelium with copper-oxidized LDL. 48 Long-term treatment of endothelial cells with high concentrations of native LDL 910 or /3-very-low-density lipoprotein 1112 also can induce monocyte binding; the role of oxidation in these effects has not been clearly defined. It is clear from all these studies that the interaction of lipoproteins with endothelial cells and leukocytes may play an important role in regulating entry of leukocytes into the vessel wall. Different lipoproteins may play a dominant role in different disease settings. We have focused on the monocyte-specific reaction induced by treating endothelial cells with MM-LDL, since this reaction resembles the predominantly monocytic response observed in fatty-streak lesions. The increase in monocyte binding induced by MM-LDL was inhibited by cycloheximide, suggesting that protein synthesis was necessary for maximal induction. 3 In the present study, we examined the biochemical and biological characteristics of the leukocyte binding molecules induced on the surface of RAECs, HUVECs, and human aortic endothelial cells (HAECs) by a 4-hour treatment with MM-LDL. The results suggest that MM-LDL treatment induces the synthesis of a binding molecule that is not E-selectin, vascular cell adhesion molecule-1 (VCAM-1), or intercellular adhesion molecule-1 (ICAM-1).
previously. 1516 The human HL 60 (ATCC CCL 240) cell line was also used as a source of neutrophil-like cells.
Lipoprotein Preparation
LDL (d= 1.019 to 1.063) was isolated from human blood by density-gradient centrifugation of serum and stored in phosphate-buffered 0.15 mol/L NaCl (PBS) containing 0.01% EDTA. MM-LDL was obtained by storage of LDL at 4°C for 3 to 6 months, by mild iron oxidation, 17 or by treatment of LDL with soybean lipoxygenase and phospholipase A,. 4 All active preparations contained 2 to 6 nmol/L thiobarbituric acidreactive substances per milligram cholesterol. After treatment with iron or soybean lipoxygenase and phospholipase A 2 , EDTA (0.3 mmol/L) and butylated hydroxytoluene (BHT) (0.1 mmol/L) were added to the lipoproteins; BHT was also added to MM-LDL obtained by storage. We and others have shown that addition of BHT to lipoproteins prevents their oxidation by copper and cells. The final concentrations of BHT and EDTA in the culture medium were 5 to 25 ^.mol/L and 15 to 70 /xmol/L, respectively. In control studies these additives had no effect on the level of monocyte binding in untreated cells, cells treated with MM-LDL, or cells treated with lipopolysaccharide (LPS). All MM-LDL preparations were tested for LPS by the chromogenic Limulus assay. 18 Preparations employed for these studies contained <50 pg/mL LPS when added to the endothelial cells. This concentration of free LPS did not induce monocyte binding (data not shown).
We have also observed, as reported previously, 3 that endothelial cells exhibit a varying susceptibility to MM-LDL; thus, wherever possible, cells from particular individuals used for screening MM-LDL preparations were used in experiments employing this MM-LDL. In particular we found that HUVECs were consistently less sensitive to the effects of MM-LDL than RAECs and that HAECs from different donors exhibited variable sensitivity. The level of a particular MM-LDL preparation necessary for maximal activity varied from 5 to 125 /xg/mL; stored MM-LDL preparations were maximally active at 5 to 20 ig/mL, whereas iron and enzymatically made MM-LDL were active at 70 to 125 ^.g/mL. Therefore, for all experiments reported in this article, dose-response curves were performed, and the dose inducing maximal binding was used.
Adhesion Assay
Confluent monolayers in 48-well dishes were rinsed two times with serum-free medium, and 2X10 5 THP-1 or monocytes in RPMI containing 1% fetal calf serum (FCS) were added to each well. After a 15-to 45-minute incubation, the nonadherent cells were removed by rinsing the wells two times with medium. This rinsing step was crucial in removing nonadherent cells; the first rinse was done by pipetting 0.5 mL of medium, with force, into the center of the well with a Pipetman; the second rinse was done by pipetting medium onto the wall of the well. After rinsing, the cells were fixed with 1% glutaraldehyde in PBS. The number of attached cells was determined visually or, in some cases, by measuring radioactivity of [ 3 H]thymidine THP-1 or HL 60 cells adherent to the monolayer. In the case of U937 and T-cell adhesion to HUVECs, radioactively labeled cells suspended in PBS were injected into adhesion chambers and allowed to interact with the endothelial monolayer for 10 minutes. The chambers were then inverted for 500 seconds to remove unattached cells as previously described. 19 All experiments were performed at least three times, with each treatment tested in 4 to 8 wells. Where visual counting was performed, three fields per well were counted at x 100 magnification with an eyepiece grid, and the average number of cells per high-power field in each well was determined. Data shown represent one of three experiments and are expressed as cells per high-power field ±SD, where n is the number of wells per treatment. In Figs 1 and 2, for which radiolabeled cells were employed, data are expressed as percentage of the total labeled cells adherent to the well. For statistical analyses, a Student's t test was performed comparing two conditions (as discussed in "Results"). Significance was taken as P<.01. In one series of studies, cells were treated for 2 minutes at 22°C with 0.01% trypsin in Dulbecco's modified Eagle's medium (DMEM), then washed two times with DMEM containing 5% fetal bovine serum (FBS), and monocytes were allowed to bind for 15 minutes in RPMI containing 1% FCS. 
Antibody Binding
HUVECs in 96-well dishes were pretreated with medium containing MM-LDL (100 ixglmV), interleukin (IL)-l (10 U/mL), or no additives for 4 hours. The wells were rinsed twice with ice-cold PBS containing calcium, magnesium, glucose, and 5% fetal bovine serum (FBS) to remove MM-LDL or other additives. Cells were then incubated with monoclonal antibodies to human E-selectin (P6E2), human VCAM-1 (P1B5), or human ICAM-1 (P3G1) for 1 hour; then peroxidase-labeled goat anti-mouse second antibodies were added for 2 hours. These antibodies were obtained from Cytel Corp (San Diego, Calif). P6E2 (an IgG 3 ) crossreacted with the E-selectin protein immunoprecipitated with H18/7 20 ; P1B5 (an IgG,) crossreacted with VCAM-1 protein immunoprecipitated by antibody 4B9 21 ; and P3G1 (an IgG|) crossreacted with ICAM-1 protein immunoprecipitated by RR1/1 obtained from Boehringer Mannheim (Indianapolis, Ind). Unbound antibodies were removed by washing, o-phenylenediamine peroxide was added, and absorbance was read at 492 nm on a Titertek Multiscan MCC/340.
Tests of Antibody Inhibition of Binding
For studies of antibody effects on endothelial cells, Fab fragments of polyclonal antibody to either fibronectin (Calbiochem, San Diego, Calif) or monocyte chemotactic protein-1 (MCP-1) (obtained from Anthony J. Valente, University of Texas, San Antonio) were prepared according to previous methods. 22 Monocytes were then added to endothelial monolayers in the presence or absence of antibody, and adhesion was determined as detailed above.
Effect of Sugars, Calcium, and Magnesium
After treatment of RAECs with MM-LDL for 4 hours, cells were rinsed with ice-cold PBS and fixed with 1% paraformaldehyde in 1 mol/L sodium cacodylate for 30 minutes at 4°C; HAECs were tested unfixed for sugar effects. To measure the effect of sugars, cells were washed two times with ice-cold PBS for fixed cells or with medium for unfixed cells. They were then incubated for 30 minutes at 4°C with THP-1 cells in the presence or absence of various sugars: lactose-1-phosphate, maltose-1-phosphate, /v'-acetylglucosamine, fructose-6-phosphate, mannose-6-phosphate, glucose-1-phosphate, and glucose-6-phosphate, all at 10" 3 mol/L. Wells were then processed as described above for adhesion assays. For studies of the effects of calcium and magnesium, a modification of previously described methods was employed. 23 To examine the effect of calcium and magnesium, THP-1 cells were rinsed twice with 1% PBS containing 1 mmol/L of EDTA or EGTA. These PBS rinses and the performance of binding in PBS lacking calcium and magnesium were essential to the inhibition of binding in the absence of added divalent cations. The THP-1 cells were then added to the endothelial cells (fixed with paraformaldehyde) with or without 3 or 6 mmol/L calcium or magnesium, and the number of adherent cells was determined as described above.
Results

Regulation of Binding
In a previous study, we showed that RAECs treated for 4 to 48 hours with MM-LDL obtained by storage were induced to bind monocytes but not neutrophils. 3 To determine whether this binding was induced by known adhesion molecules, human cells had to be used, because available antibodies were reactive only with human adhesion molecules. Four-hour pretreatment of HUVECs with MM-LDL at 100 figlmL induced a 4.7-fold increase in the adhesion of THP-1 cells to the endothelial cells (Fig 1; P<.0001 ). This increase was similar to that seen with IL-1 pretreatment (10 U/mL). (A similar increase in binding to HAECs was observed.) HL 60 cell adhesion was not significantly stimulated by MM-LDL but was stimulated by IL-1 (Fig 1) . In a separate experiment, the effect of MM-LDL on the binding of lymphocytes to HUVECs was examined. Pretreatment of HUVECs with MM-LDL (100 fig/mL for 4 hours) induced binding of U937 cells, a monocytic cell line, but did not induce lymphocyte binding to the endothelial cells; however, lymphocyte binding was increased by fourfold with LPS (10 ng/mL) pretreatment (Fig 2, P<. 
for MM-LDL versus untreated cells).
Expression of Known Adhesion Molecules on MM-LDL-Treated Cells
Treatment of HUVECs or HAECs for 4 hours with IL-1 induced E-selectin, VCAM-1, and ICAM-1 expression; however, none of these molecules was significantly induced by a 4-hour treatment with MM-LDL (Fig 3) . In fact, in this study, the amount of ICAM-1 detected was decreased, whereas in a separate study employing another monoclonal antibody (R6. 
Effect of Antibodies to MCP-1 and Fibronectin on Monocyte Binding
To determine whether MCP-1 or fibronectin was involved in monocyte binding, endothelial cells were pretreated with Fab fragments of polyclonal antibodies to fibronectin or MCP-1 and then tested for monocyte binding. The Fab fragment of MCP-1 completely inhibited monocyte chemotaxis, showing that it was able to block the action of MCP-1. The Fab fragment of fibronectin antibody was shown to block the adhesion of monocytes to fibronectin-coated a. dishes. Neither of these antibodies significantly altered binding of monocytes to untreated cells or to cells treated for 4 hours with MM-LDL (Fig 4) . By enzyme-linked immunosorbent assay, it was shown that fibronectin was not exposed by treating cells with MM-LDL (data not shown).
Characteristics of the Monocyte-Binding Molecule Induced By MM-LDL
Treating RAECs for 1 hour with cydoheximide (1 Mg/mL) or for 2 hours with tunicamycin (4 /xg/mL) before the addition of the MM-LDL caused a 60% reduction in THP-1 cell binding (Fig 5) . Under the conditions employed, cydoheximide inhibited protein synthesis by 80%, whereas tunicamycin had no effect on total protein synthesis but inhibited incorporation of [ 3 H]glucosamine into protein by 35% to 60%. The data suggest that the binding molecule is a glycoprotein. Further evidence that the monocyte binding molecule is a protein comes from studies in which cells were treated with a low level of trypsin before binding was measured (Table) . HAECs were treated for 4 hours with MM-LDL, and binding of monocytes was tested before and after treatment with 0.01% trypsin, a level that does not cause cell rounding or detachment. The monocyte binding induced by MM-LDL was completely abolished by trypsin treatment (Table) .
The effect of several sugars on THP-1 cell adhesion to RAECs and HAECs was tested. When sugars were added to endothelial cells before binding was per- formed but were not present during binding, no inhibition of binding was observed. However, when sugars were present during binding, lactose-1-phosphate, maltose-1-phosphate, and ,/V-acetylglucosamine blocked the binding by 90% to 100% (Fig 6) . The other sugars, including mannose-6-phosphate, fructose-6-phosphate, glucose-1-phosphate, and glucose-6-phosphate, did not inhibit binding (P<.001 for inhibition by specific sugars). To determine whether calcium or magnesium was necessary for MM-LDL-induced binding, THP-1 cells were resuspended in medium with EDTA or EGTA. EDTA and EGTA treatment reduced binding to RAECs by more than 90%, which could be reversed by the addition of calcium or magnesium (Fig 7) .
Discussion
The present studies show that treatment of human endothelial cells with MM-LDL for 4 hours induces the binding of monocytes and monocytic cell lines but not neutrophils or lymphocytes (Figs 1 and 2) . The monocyte binding molecule(s) induced by MM-LDL appears to be a protein, since cycloheximide blocked induction of monocyte binding (Fig 5) and treatment of MM-LDL-stimulated cells with low levels of trypsin completely abolished binding (Table) .
Several groups have shown that binding of leukocytes to endothelial monolayers in a flowing system involves several steps, including rolling, leukocyte activation, and sticking.
2426 These steps are mediated by different adhesion molecules. We have examined the role of three important adhesion molecules, E-selectin, VCAM-1, and ICAM-1, and a major monocyte activator, MCP-1, in mediating the monocyte adhesion induced by a 4-hour treatment with MM-LDL. The known adhesion molecules that we have examined have been shown to be increased by a number of endothelial activators.
E-selectin has been cloned by Bevilacqua et al 2027 and mediates binding of neutrophils, monocytes, and a subset of T lymphocytes. reaching a maximal level after 2 to 4 hours and disappearing by 24 hours. E-selectin is a member of the selectin family, which includes P-selectin and L-selectin (murine MEL-14 and its human homologues LAM-1, Leu8, and DREG, reviewed in Reference 32). All these proteins express the iV-terminal calcium-dependent carbohydrate recognition domains in which sugar moieties are important for binding. 32 30 Its expression is increased by 6-hour treatment and is maintained for at least 48 hours. 37 The ICAM-1 molecule is a member of the immunoglobulin supergene family.
38
-39 VCAM-1, described by Osborn et al, 40 is induced by a 3-hour exposure to IL-1 and TNF-a or LPS and is sustained for 48 to 72 hours. It binds monocytes and lymphocytes but not neutrophils. 21 -40 VCAM-1 belongs structurally to a subset of the immunoglobulin supergene family, and VLA-4 integrin is known to be a ligand for VCAM-1. 41 Cybulsky and Gimbrone 8 have described the presence of VCAM-1 on lesions in Watanabe heritable hyperlipidemic rabbits; however, it was not seen on human lesions.
In this study we have shown that surface expression of E-selectin, VCAM-1, and ICAM-1 was not induced by treatment of endothelium for 4 hours with MM-LDL (Fig 3) . It should be noted that monocyte binding induced by MM-LDL persists for at least 24 hours after MM-LDL exposure, and the present data do not exclude a role for these three adhesion molecules after exposure times longer than 4 hours. MCP-1 has been shown to be a major monocyte activator 42 and to be increased in atherosclerotic lesions. 43 We have previously demonstrated that exposure of HAECs and human aortic smooth muscle cells to MM-LDL caused an increase in synthesis of MCP-1. 44 It Initial characterization of the binding molecule(s) induced by a 4-hour treatment with MM-LDL suggests that binding is mediated, at least in part, by specific carbohydrates on the monocytes or endothelial cells. Lactose-1-phosphate, maltose-1-phosphate, and A/-acetylglucosamine inhibited monocyte binding induced by MM-LDL, whereas fructose-6-phosphate, glucose-1-phosphate, glucose-6-phosphate, and mannose-6 phosphate had no effect (Fig 6) . Specific carbohydrates have been shown to play a role in binding of a number of molecules to cell surfaces, including antibodies, toxins, bacteria, and adhesion molecules. 45 The most thoroughly studied proteins are the C-lectins, including the members of the selectin family of adhesion molecules, which require calcium for binding, and the S-lectins, which require free thiols but not divalent cations for stable binding to their ligands. 46 In addition, glycosylation has recently been shown to play a role in the binding of ICAM-1, a member of the immunoglobulin supergene family, to MAC-1, 47 suggesting that some adhesive interactions in this family may also be mediated by carbohydrates. Another characteristic of the adhesion molecule induced by MM-LDL is that it requires divalent cations, either calcium or magnesium, for binding (Fig 7) . Calcium has been shown to be strictly required for binding of all known members of the selectin family to their ligands. 48 It has also been shown that the binding of VLA-4 to VCAM-1 is facilitated by both calcium and magnesium. 49 Thus, endothelial cell binding molecules in the major adhesion molecule families have been described that display one or both characteristics of the molecule(s) induced by MM-LDL. MM-LDL is unique among endothelial activators in inducing binding of monocytes but not neutrophils. TNF-a, IL-1/3, LPS, and thrombin all induce the binding of both monocytes and neutrophils by inducing E-selectin, VCAM-1, and ICAM-1. Thus, it appears that MM-LDL activates endothelial cells by a different pathway than the other endothelial activators. In a separate study we have shown that the major second messenger for the action of MM-LDL is cyclic AMP (cAMP)." It has been shown by others that cAMP can inhibit the ability of TNF to induce E-selectin and VCAM-1. 50 One possible cause for the lack of induction of E-selectin or VCAM-1 by MM-LDL is the high levels of cAMP generated by treatment of cells with MM-LDL.
We propose that chronic inflammatory processes, at least in part, are mediated by different second messengers, and thus, different binding molecules may be involved than in acute inflammatory processes. The binding molecule(s) induced by MM-LDL and described in this article may be one such molecule. The particular role in the adhesion process played by this molecule(s) will be determined in future studies using assays in which adhesion is assessed under flow conditions.
